FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending January 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held within the 
US Retirement Savings Plan (the "Plan",) 
which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned 
persons 
on 13 January 2009 of an 
increase in the notional allocation of Ordinary Share ADRs on 
9 January 2009
 at a price of $
38.90
 per ADR:-

Dr M Slaoui
15
Mr W C Louv
8
Dr D Pulman
11



This 
notification
 relates to a 
transaction notified in accordance with
 
Disclosure
 and Transparency Rule 3.1.4R(1)(a
).

S M Bicknell
Company Secretary

13 January 2009

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: January 13, 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc